Business
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"text","content":" PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--\nHarmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30 – September 3, 2025, at the Lisbon Congress Centre in Lisbon, Portugal.\n\n\nPoster presentations will highlight information from the company’s investigation of EPX-100 (clemizole hydrochloride) in two Phase 3 clinical studies (ARGUS and LIGHTHOUSE) for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, respectively.\n\n\nBoth trials are currently enrolling and more information about the trials can be found at argustrial.com and lighthouselgsstudy.com.\n\n\nThe posters will be on display from Sunday, August 31 – Tuesday, September 2, from 1:45 pm -3:15 pm GMT. Poster presentation details are listed below:\n\n\n\n\nAbstract Title:\n\n\n\n\n\n\nARGUS: A Phase 3 Study of EPX-100 (Clemizole Hydrochloride) in Patients with Dravet Syndrome\n\n\n\n\n\n\n\n\nDate/Time:\n\n\n\n\n\n\nSunday, August 31; 2pm – 2:30 pm GMT (Part of the ILAE YES (Young Epilepsy Section) poster tour)\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nAbstract Title:\n\n\n\n\n\n\nA 20-Week Multicenter, Randomized, Double-Blind (DB), Placebo-Controlled, Phase 3 Trial (EPX 100-003) evaluating EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in patients with Lennox-Gastaut Syndrome (LGS)\n\n\n\n\n\n\n\n\nDate:\n\n\n\n\n\n\nSunday, August 31 (Note – not part of the ILAE YES poster tour)\n\n\n\n\n\n\n\nAbout Clemizole Hydrochloride (EPX-100)\n\n\nEPX-100, clemizole hydrochloride, is under development for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). EPX-100 acts by targeting central 5-hydroxytryptamine receptors to modulate serotonin signaling. The drug candidate is administered orally twice a day in a liquid formulation and has been developed based on a proprietary phenotype-based zebrafish drug screening platform. DS is caused by a loss of function mutation in the SCN1A gene, and scn1 mutant zebrafish replicate the genetic etiology and phenotype observed in the majority of DS patients. The scn1Lab mutant zebrafish model that expresses voltage gated sodium channels has been used for high-throughput screening of compounds that modulate Nav1.1 in the central nervous system.\n\n\nAbout Dravet Syndrome\...